(Last)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| l | OMB APPROVAL | | | | | | | | | |
|---|--------------------------|-----------|--|--|--|--|--|--|--|--|
| | OMB Number: | 3235-0287 | | | | | | | | |
| l | Estimated average burden | | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

1. Name and Address of Reporting Person*

(First)

C/O VERTEX PHARMACEUTICALS

BOGER JOSHUA S

1. Title of Security (Instr. 3)

Common Stock

hours per response: 0.5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / Director 10% Owner MA [VRTX] Officer (give title Other (specify below) below) 3. Date of Earliest Transaction (Month/Day/Year) 10/19/2016

INCORPORATED 50 NORTHERN AVENUE (Street) **BOSTON** 02210 MA (City) (State) (Zip)

(Middle)

4. If Amendment, Date of Original Filed (Month/Day/Year) Line)

6. Individual or Joint/Group Filing (Check Applicable

Form filed by One Reporting Person Form filed by More than One Reporting Person

7. Nature

of Indirect

Beneficial

(Instr. 4)

Trust

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 2. Transaction 2A. Deemed 5. Amount of 6. Ownership Execution Date, Transaction Form: Direct Securities (Month/Day/Year) Beneficially if any Code (Instr. (D) or Indirect (Month/Day/Year) 8) Owned Following (I) (Instr. 4) Reported (A) or (D) Transaction(s) ν Price Code Amount (Instr. 3 and 4) 10/19/2016 М 6,500 \$36.3 274,725 Α D $S^{(1)}$ 10/19/2016 6,300 D \$81.82(2)(3) 268,425 D

Common Stock Common Stock 10/19/2016 S⁽¹⁾ 200 D \$82.55 268,225 D 13,286 Ι 401k Common Stock Common Stock Common Stock 78,200 T Held In

> Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| | (e.g., puts, cans, warrants, options, convertible securities) | | | | | | | | | | | | | | |
|---|---|--|---|------------------------------|---|-----|-------|--|--------------------|--|--|---|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock Option (Right to Buy) | \$36.3 | 10/19/2016 | | M | | | 6,500 | (4) | 01/23/2017 | Common Stock | 6,500 | \$0.00 | 79,500 | D | |

Explanation of Responses:

- 1. Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- 2. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 3. Open market sales reported on this line occurred at a weighted average price of \$81.82 (range \$81.37 to \$82.35).
- 4. Fully vested.

Remarks:

Omar White, Attorney-In-Fact 10/21/2016

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.